Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $15.00 price target on the stock. D. Boral Capital’s price objective points to a potential upside of 173.22% from the company’s current price.

Several other analysts have also issued reports on COYA. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, November 11th.

Coya Therapeutics Stock Performance

Shares of NASDAQ COYA traded up $0.11 during mid-day trading on Tuesday, reaching $5.49. The company’s stock had a trading volume of 6,821 shares, compared to its average volume of 59,403. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69. The stock has a market capitalization of $91.74 million, a P/E ratio of -8.45 and a beta of 0.46. The stock has a 50-day moving average of $5.98 and a two-hundred day moving average of $6.48.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. Analysts predict that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Insider Activity

In related news, CEO Arun Swaminathan bought 5,000 shares of Coya Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average price of $7.34 per share, with a total value of $36,700.00. Following the purchase, the chief executive officer now owns 5,000 shares in the company, valued at $36,700. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders bought a total of 9,510 shares of company stock worth $69,615 over the last 90 days. 9.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Coya Therapeutics in the 2nd quarter worth $101,000. Finally, GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics in the 3rd quarter valued at about $169,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.